SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending after delivering a strong earnings beat and significantly raised FY27 guidance, with robust cloud and AI infrastructure growth, leading the community to hail it as a validation of AI spending and a powerful rebuttal to prior capital expenditure concerns plaguing the software sector.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is experiencing significant volatility, driven by strong AI-fueled earnings from Oracle providing a bullish catalyst, alongside ongoing geopolitical tensions in the Middle East and conflicting reports impacting oil routes. The community is actively debating whether market movements are algorithmic 'pumps' or fundamental shifts, as traders anticipate upcoming economic data.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the FDA lifts its Complete Response Letter for the Duchenne Muscular Dystrophy therapy, Deramiocel, and sets a new PDUFA date, a development celebrated by the community eager for accelerated approval and potential buyout after a controversial FDA official's imminent departure. Investors are also keenly anticipating high-impact data from an upcoming medical conference and updates on the promising StealthX exosome platform.

UniFirst Corp. engages in the provision of workplace uniforms and protective work wear clothing. It operates through following segments: the United States and Canadian Rental and Cleaning, Manufacturing (MFG), Specialty Garments, First Aid, and Corporate. The U.S. and Canadian Rental and Cleaning segment purchases, rents, cleans, delivers, and sells uniforms, protective clothing, and non-garment items. The MFG segment designs and manufactures uniforms and non-garment items. The Specialty Garments segment is involved in nuclear and cleanroom applications and provides cleanroom cleaning services. The First Aid segment focuses on first aid cabinet services and other safety supplies. The Corporate segment includes distribution, sales and marketing, information systems, engineering, materials management, manufacturing planning, finance, budgeting, human resources, and other general and administrative costs and interest expense. The company was founded by Aldo Croatti in 1936 and is headquartered in Wilmington, MA.

Unifirst Corp.

UniFirst is trending as Cintas has announced a definitive agreement to acquire the uniform rental company, marking a significant development after a prolonged M&A saga. The community is actively discussing the substantial acquisition premium and the broader consolidation within the uniform services sector.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath (PATH) is experiencing heightened investor attention leading into its upcoming earnings report, with recent AIUC-1 certification underscoring its pivotal role in secure enterprise AI agent orchestration. This has fueled a polarized community debate, with bulls anticipating a significant short squeeze and fundamental strength in Agentic AI, while bears express concerns over competition and valuation, driving notable price volatility.

TSS, Inc. engages in the provision of comprehensive services for the planning, design, development and maintenance of mission-critical facilities and information infrastructure as well as integration services. It operates through the Facilities and Systems Integration Services business segments. The Facilities segment consists of the design, project management, and maintenance of data center and mission-critical business operations. The Systems Integration segment integrates information technology equipment for original equipment manufacturer vendors and customers to be used inside data center environments, including modular data centers. The company was founded by Gerard J. Gallagher on December 20, 2004 and is headquartered in Round Rock, TX.

TSS Inc

TSSI is trending ahead of its highly anticipated Q4 earnings, with community sentiment driven by an earlier-than-expected release date and strong tailwinds from key partner Dell's surging AI server backlog. Investors are closely watching for a potential beat and positive guidance, fueled by the company's low float, high short interest, and its critical role in the ongoing AI data center infrastructure buildout.

Canadian Solar, Inc. engages in the manufacture of solar photovoltaic modules, provision of solar energy and battery storage solutions, and development of utility-scale solar and battery storage products. It operates through the CSI Solar and Global Energy segments. The CSI Solar segment designs, develops, and manufactures solar ingots, wafers, cells, modules, and other solar power and battery storage products. The Global Energy segment includes solar and battery storage project development and sale, asset management services for operational projects, sale of electricity, and investment in retained assets. The company was founded by Shawn Qu in October 2001 and is headquartered in Kitchener, Canada.

Canadian Solar Inc

The community is intensely debating Canadian Solar's valuation, alleging market manipulation and "fraud prints" that keep its price artificially low despite a recent notes offering at a substantial premium and positive news like a key patent win. Investors eagerly anticipate upcoming Q4 earnings and long-term tailwinds from US manufacturing and growing energy storage demand.

The Internet Computer is a decentralized cloud blockchain designed to run applications, websites, and backend systems fully on-chain. Its architecture provides robust security, resilience, and built-in multi-chain support.  A key focus of the network is enabling a “self-writing cloud,” where AI tools allow users generate applications through natural-language instructions.  Developers and users can experiment with the platform using AI app-generation tools like caffeine.ai or by writing serverless code directly through online IDEs such as icp.ninja.  The ICP token is used to pay for computation (through a burn-based model) and to participate in network governance through staking.

Internet Computer

Internet Computer (ICP) is a hot topic, fueled by discussions around its Mission 70 initiative to reduce inflation and growing real-world adoption with projects like the Swiss Subnet and AI integrations. While many see its unique decentralized infrastructure as a long-term asymmetric bet, others remain skeptical, citing historical price underperformance and concerns over continuous token minting.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

Serve Robotics is trending as its acquisition of Diligent Robotics signals an expansion into healthcare, while NVIDIA's public endorsement highlights its "Physical AI" in urban delivery. The community is actively debating the company's growth potential and short-squeeze prospects, balancing optimism from new markets and partnerships against valuation and profitability concerns.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is trending as its updated executive compensation, including potential "golden parachutes," fuels widespread community speculation about a significant M&A or takeover within the consolidating AI data training sector. Investors are closely watching upcoming earnings for clarity on the company's ambitious growth trajectory in areas like defense and AI robotics, debating whether conservative guidance will be exceeded or if it will become an acquisition target.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>While Microbot's corporate headquarters are in the U.S., the heart of its technical development is its facility in the Caesarea Business and Industrial Park in Israel.</li><li>The company said it maintains sufficient Liberty system inventory in the U.S. to support current customers and is building additional stock to meet anticipated demand.</li></ul>Israel-founded Microbot Medical Inc. (MBOT) said on Tuesday that it is not experiencing any business disruption due to geopolitical events but is actively building additional stock in the U.S. to meet anticipated demand for its Liberty system.Shares of the company, however, traded 3% lower at the time of writing.<h2 class="st-heading-2">Microbot’s Assurance</h2>Microbot <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/03/03/3248415/0/en/Microbot-Medical-Confirms-Continued-Operational-and-Commercial-Stability-Amid-Current-Geopolitical-Event.html">said</a> that it is not experiencing any disruption in either the U.S. or Israel with all personnel continuing to operate as usual and both internal operations and the lead manufacturing partner remaining fully functional.The FDA approved Microbot’s Liberty Endovascular Robotic System, a single-use, remotely operated robotic system for peripheral endovascular procedures, in September 2025. The company said that its commercial focus is now on the U.S. Market which is managed by its U.S.-based commercial team in Hingham.“This ensures uninterrupted service, reliable distribution, and continued advancement of the limited market release of the LIBERTY System as planned,” the company said. It added that the company maintains sufficient inventory in the U.S. to support current customers and is building additional stock to meet anticipated demand. The additional stock is being built through the company's U.S.-based third party logistics partner, it said.“The Company is closely monitoring the situation in the Middle East to ensure the ongoing well-being of its employees and to ensure uninterrupted support for customers, reinforcing its commitment to operational excellence,” it added.While Microbot's corporate headquarters are in the U.S., the heart of its technical development is its facility in the Caesarea Business and Industrial Park in Israel.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, the retail sentiment around MBOT stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.<a href="https://stocktwits.com/symbol/MBOT">MBOT stock</a> has risen 76% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/mdb-stock-sees-biggest-single-day-decline-on-record-wall-street-cuts-price-targets-on-slower-atlas-growth-and-cautious-outlook/cZdekxtRIPK">MDB Stock Sees Biggest Single-Day Decline On Record: Wall Street Cuts Price Targets On Slower Atlas Growth And Cautious Outlook</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

MBOT Stock Falls As Investors Ponder Impact Of Geopolitical Tensions On Israel-Founded Company

Microbot said on Tuesday that it is not experiencing any disruption in either the U.S. or Israel with all personnel continuing to operate as usual. 

Equity

Microbot said on Tuesday that it is not experiencing any disruption in either the U.S. or Israel with all personnel continuing to operate as usual. 


Microbot Medical (NASDAQ:MBOT) Stock Price Crosses Above 200 Day Moving Average - Here's What Happened

Microbot Medical (NASDAQ:MBOT) Share Price Crosses Above Two Hundred Day Moving Average - What's Next...

$38M Defense Backlog vs. $6M Market Cap, Breakthrough Biotech Data, and the Quantum Security Land Grab

Markets are heading into the close, with a series of high-impact corporate developments that are reshaping narratives across defense, biotech, cybersecurity, robotics, and enterprise software. Several small- and mid-cap names are flashing disconnects between fundamentals and valuation, in some cases dramatically so. NAPC Defense (OTCID:BLIS) announced $38M in new and recently finalized U.S. government task orders

Microbot Medical (NASDAQ:MBOT) Posts Earnings Results, Misses Expectations By $0.01 EPS

Microbot Medical (NASDAQ:MBOT - Get Free Report) released its quarterly earnings data on Wednesday. The biotechnology company reported ($0.07) earnings per share for the quarter, missing the...

Down 28.2% in 4 Weeks, Here's Why You Should You Buy the Dip in Microbot Medical (MBOT)

Microbot Medical (MBOT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Stereotaxis Rolls Out Synchrony System in EU and Files for FDA Approval

STXS expands its digital surgery vision with the EU launch of its Synchrony System and an FDA submission for market entry.

All You Need to Know About Microbot Medical (MBOT) Rating Upgrade to Buy

Microbot Medical (MBOT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Microbot Shares Rise on FDA Clearance for LIBERTY Robotic System

MBOT shares rise as FDA clears its LIBERTY robotic system, paving the way for U.S. market entry and fueling strong investor momentum.

Microbot Shares Rise as New U.S. Patent Expands LIBERTY System Market

MBOT's new U.S. patent boosts the LIBERTY system's flexibility, expanding its U.S. market reach to over six million annual procedures.

Microbot Medical (MBOT) Upgraded to Buy: What Does It Mean for the Stock?

Microbot Medical, Inc. is a pre-clinical medical device company engaged in the research, design, development, and commercialization of micro-robotics assisted medical technologies. The firm carries out its operations through the ViRob and TipCat platforms. The ViRob platform technology is an autonomous crawling micro-robot that can be controlled remotely or within the body. It makes use of the Self-Cleaning Shunt, a robotic system designed as the ventricular catheter portion of a Cerebrospinal Fluid shunt system and is mainly used for the treatment of hydrocephalus and Normal Pressure Hydrocephalus. The TipCat platform, a self-propelling, flexible, and semi-disposable endoscope, provides see-and-treat capabilities within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. The company was founded by Harel Gadot, Moshe Shoham, and Yosseph Bornstein on August 2, 1988 and is headquartered in Hingham, MA.

MBOT
Microbot Medical Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest MBOT News

MBOTMicrobot Medical Inc